tiprankstipranks
TScan Therapeutics (TCRX)
NASDAQ:TCRX
US Market

TScan Therapeutics (TCRX) Income Statement

Compare
214 Followers

TScan Therapeutics Income Statement

Last quarter (Q3 2024), TScan Therapeutics's total revenue was $1.05M, a decrease of -73.01% from the same quarter last year. In Q3, TScan Therapeutics's net income was $-29.89M. See TScan Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 21.05M$ 13.54M$ 10.14M$ 1.08M$ 0.00
Gross Profit
$ -67.10M$ 8.40M$ 6.81M$ -19.49M$ -519.00K
Operating Expenses
$ 114.51M$ 80.17M$ 58.78M$ 27.32M$ 14.21M
Depreciation and Amortization
$ 5.36M$ 5.14M$ 3.33M$ 1.23M$ 519.00K
EBITDA
$ -80.10M$ -59.91M$ -45.30M$ -25.00M$ -13.69M
Operating Income
$ -93.46M$ -66.64M$ -48.64M$ -26.23M$ -14.21M
Other Income/Expenses
$ 4.24M$ 415.00K$ 16.00K$ 106.00K$ 552.00K
Pretax Income
$ -89.22M$ -66.22M$ -48.63M$ -26.13M$ -13.66M
Net Income
$ -89.22M$ -65.81M$ -48.63M$ -26.02M$ -13.11M
Per Share Metrics
$ ―$ ―$ ―$ ―$ ―
Basic EPS
$ -1.36$ -2.74$ -2.03$ -1.04$ -0.53
Diluted EPS
$ -1.36$ -2.74$ -2.03$ -1.04$ -0.53
Weighted Average Shares Outstanding
65.60M 24.05M 23.91M 24.94M 24.94M
Weighted Average Shares Outstanding (Diluted)
65.60M 24.05M 23.91M 24.94M 24.94M
Currency in USD

TScan Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis